晚期滤泡性淋巴瘤诱导后应答适应策略:FOLL12研究
PURPOSE: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy.…
要点
- 标准2年利妥昔单抗维持治疗优于代谢和分子学应答适应的诱导后策略。
核心结论
- 基于代谢和分子学应答的诱导后适应治疗与2年利妥昔单抗维持相比,PFS显著更差。
- 标准利妥昔单抗维持的优越性在亚组分析中得到证实,尤其在达到完全代谢缓解且MRD阴性的患者中。
研究设计与样本
- 随机对照非劣效性试验,纳入807例初治晚期高肿瘤负荷滤泡性淋巴瘤患者。
- 实验组根据完全代谢缓解(CMR)和微小残留病(MRD)状态接受观察、利妥昔单抗或替伊莫单抗治疗。
关键数值与推荐
- 完全代谢缓解且MRD阴性患者实验组接受观察。
- 完全代谢缓解但MRD阳性患者接受利妥昔单抗四剂每周一次,最多三疗程,直至MRD阴性。
- 非完全代谢缓解患者接受一剂替伊莫单抗后标准利妥昔单抗维持。
临床怎么用
- 对于晚期高肿瘤负荷滤泡性淋巴瘤诱导后应答患者,标准2年利妥昔单抗维持仍是优先选择。
- 基于代谢和分子学应答的适应策略可能导致PFS下降,尤其对达到CMR和MRD阴性的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS: We randomly assigned treatment-naïve, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS: Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n = 65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION: A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRD-negative.
引用
- Luminari S, Manni M, Galimberti S, et al. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol. 2021. PMID: 34709880. doi:10.1200/JCO.21.01234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。